Development of LY2334737, an oral gemcitabine prodrug for continuous administration. Perspectives for the therapy of mature T-cell and NK-cell lymphomas. Hematology Meeting Reports (formerly Haematologica Reports), [S. l.], v. 3, n. 1, 2009. DOI: 10.4081/hmr.v3i1.533. Disponível em: https://journals.pagepress.org/hmr/article/view/533. Acesso em: 20 jun. 2025.